Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension Period
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 60
- Registration Number
- NCT03414736
- Locations
- 🇺🇸
Investigational Site Number 8400003, Knoxville, Tennessee, United States
🇺🇸Investigational Site Number 8400002, Saint Paul, Minnesota, United States
🇺🇸Investigational Site Number 8400001, Austin, Texas, United States
A Drug-Drug Interaction Study Between Sotagliflozin and Ramipril
- Conditions
- Healthy SubjectsDiabetes Mellitus
- Interventions
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 16
- Registration Number
- NCT03414723
- Locations
- 🇩🇪
Investigational Site Number 2760001, Berlin, Germany
Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
- Conditions
- Hypercholesterolaemia
- Interventions
- Device: Current auto-injector device (AI)Device: New auto-injector device (SYDNEY)
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 69
- Registration Number
- NCT03415178
- Locations
- 🇺🇸
Investigational Site Number 8400022, Summerville, South Carolina, United States
🇺🇸Investigational Site Number 8400017, Jacksonville, Florida, United States
🇺🇸Investigational Site Number 8400013, Ponte Vedra, Florida, United States
Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mL
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 170
- Registration Number
- NCT03406000
- Locations
- 🇧🇷
Investigational Site Number 076011, Ribeirão Preto, Brazil
🇧🇷Investigational Site Number 076002, Goiânia, Brazil
🇧🇷Investigational Site Number 076006, São José dos Campos, Brazil
A Drug to Drug Interaction Study of Sotagliflozin With Hydrochlorothiazide
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2018-01-02
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 16
- Registration Number
- NCT03387657
- Locations
- 🇺🇸
Investigational Site Number 8400001, Dallas, Texas, United States
Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants
- Conditions
- Asthma
- Interventions
- Drug: Placebo for SAR440340Drug: Placebo for dupilumab
- First Posted Date
- 2018-01-02
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 296
- Registration Number
- NCT03387852
- Locations
- 🇲🇽
Investigational Site Number 4840004, Durango, Mexico
🇺🇸Investigational Site Number 8400014, Milwaukee, Wisconsin, United States
🇺🇸Investigational Site Number 8400021, Ann Arbor, Michigan, United States
An Observational Study on Sarilumab-exposed Pregnancies
- Conditions
- Rheumatoid Arthritis -Exposure During Pregnancy
- Interventions
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 113
- Registration Number
- NCT03378219
- Locations
- 🇨🇦
CANADA, Canada, Canada
🇺🇸United States, New York, New York, United States
A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 24
- Registration Number
- NCT03376802
- Locations
- 🇺🇸
Investigational Site Number 8400001, Orlando, Florida, United States
🇺🇸Investigational Site Number 8400002, Baton Rouge, Louisiana, United States
Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies
- Conditions
- Prostate CancerNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2017-12-11
- Last Posted Date
- 2022-05-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 44
- Registration Number
- NCT03367819
- Locations
- 🇨🇳
Investigational Site Number 1580002, Tainan, Taiwan
🇬🇧Investigational Site Number 8260001, Sutton, Surrey, United Kingdom
🇺🇸Investigational Site Number 8400007, Atlanta, Georgia, United States
Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: INSULIN GLARGINE (HOE901)
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 384
- Registration Number
- NCT03359837
- Locations
- 🇨🇳
CHINA, China, China